Metraipolis › archive › dc_2febb6fd6264
A long noncoding RNA-based serum signature predicts ado-trastuzumab emtansine (T-DM1) treatment benefit in HER2+ metastatic breast cancer patients: a… — Europe PMC PMID:40925917
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40925917
- DOI
- 10.1038/s41420-[numero omesso]-8
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T01:29:21.151Z
- SHA-256 of the archived text
9d016dc7c609e97f157b01a526dacd028c7fc4025011f3c250399c111368ea8f- Stable URL of this page
https://metraipolis.com/documento/dc_2febb6fd6264
How to cite
A long noncoding RNA-based serum signature predicts ado-trastuzumab emtansine (T-DM1) treatment benefit in HER2+ metastatic breast cancer patients: a… — Europe PMC PMID:40925917 — Europe PMC (en), https://europepmc.org/article/MED/40925917 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2febb6fd6264 (Metraipolis archive dc_2febb6fd6264, sha256 9d016dc7c609e97f157b01a526dacd028c7fc4025011f3c250399c111368ea8f)
BibTeX
@misc{dc2febb6fd6264,
title = {A long noncoding RNA-based serum signature predicts ado-trastuzumab emtansine (T-DM1) treatment benefit in HER2+ metastatic breast cancer patients: a… — Europe PMC PMID:40925917},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40925917},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2febb6fd6264; sha256 9d016dc7c609e97f157b01a526dacd028c7fc4025011f3c250399c111368ea8f},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40925917. Agents can read the archived copy with the MCP tool read_document.